CT-4201
Part of the metabolic pathway of CT-4201. See the timeline on the metabolic highway.
Overview
CT-4201 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder. It is a prodrug of the tryptamine psychedelic psilocin that is said to have improved pharmacokinetic properties compared to psilocybin, the primary active constituent of psilocybin-containing mushrooms. CT-4201 is being developed by CaaMTech. As of November 2024, it is in the preclinical research stage of development.[1–5] WP
Chemistry
Harm reduction information
No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.
User reports
Erowid erowid.org
ListingsBluelight bluelight.org
ListingsReddit reddit.com
ListingsPop culture
No references added yet.
Add a reference
Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.
Opens when accounts launch.
Sources
- Other Delving into the Latest Updates on CT-4201 with Synapse. 8 May 2025
- Other Haichin M. Psychedelics Drug Development Tracker
- Other FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment. 14 November 2024
- Other CaaMTech receives FDA endorsement for psilocin depression drug development. 14 November 2024
- Other CaaMTech Receives Regulatory Validation for Functional Unblinding Strategy in Psilocin Prodrug Trial. 15 November 2024
Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.